Moderna is offering good news from the company's phase 3 trials.

Preliminary results show Moderna's COVID-19 vaccine is more than 90% effective for at least six months after vaccination.

The vaccine was also found to be more than 95% effective against severe disease.

To date, the company has delivered about 132 million doses of its vaccine globally.

Moderna also announced its trials for kids 12-17 is fully enrolled with about 3,000 U.S. participants, and its trials for children 6 months through 11 years old is in the process of enrolling.